TNF Pharma, DADA2 Foundation partner for isomyosamine compassionate use

TNF Pharmaceuticals (TNFA) announced it has formed a philanthropic collaboration with the DADA2 Foundation. The parties expect to initiate a Compassionate Use study evaluating TNF’s lead candidate isomyosamine as a potential treatment for DADA2, a rare pediatric autoinflammatory disease. TNF stated that its TNF-alpha inhibitor, isomyosamine, is an orally administered small molecule believed to be a potential superior alternative for treating DADA2.